News >

Olaratumab to Be Withdrawn From Market, Access Program Planned in Soft Tissue Sarcoma

Gina Columbus @ginacolumbusonc
Published: Friday, Apr 26, 2019

Anne White

Anne White
Eli Lilly and Company has announced that it is withdrawing its PDGFRα antagonist olaratumab (Lartruvo) from the market for the treatment of patients with advanced soft tissue sarcoma (STS), following the disappointing findings of the phase III ANNOUNCE trial.1

In the study, the combination of olaratumab and doxorubicin missed the primary endpoint of overall survival (OS) nor did it confirm a clinical benefit for patients with advanced or metastatic STS compared with standard doxorubicin.2 Moreover, the OS endpoint in the leiomyosarcoma subpopulation was also not met. Full data from the ANNOUNCE trial (NCT02451943) will be presented at an upcoming 2019 ASCO Annual Meeting and published in an upcoming journal.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication